Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry / F. Marchesi, J. Salmanton-García, C. Buquicchio, F. Itri, C. Besson, J. Dávila-Valls, S. Martín-Pérez, L. Fianchi, L. Rahimli, G. Tarantini, F.I. Grifoni, M. Sciume, J. Labrador, R. Cordoba, A. López-García, N.S. Fracchiolla, F. Farina, E. Ammatuna, A. Cingolani, D. García-Bordallo, S.K. Gräfe, Y.M. Bilgin, M. Dargenio, T.J. González-López, A. Guidetti, T. Lahmer, E. Lavilla-Rubira, G. Méndez, L. Prezioso, M. Schönlein, J. Van Doesum, D. Wolf, D.S. Hersby, F. Magyari, J. Van Praet, V. Petzer, C. Tascini, I. Falces-Romero, A. Glenthøj, O.A. Cornely, L. Pagano. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - 16:1(2023 Apr 01), pp. 32.1-32.5. [10.1186/s13045-023-01423-7]

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

F.I. Grifoni;M. Sciume;F. Farina;A. Guidetti;
2023

Abstract

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
COVID-19; Hematologic malignancies; Passive immunization; Tixagevimab/cilgavimab
Settore MED/15 - Malattie del Sangue
1-apr-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
JHematolOncol_2023_Article_1423.pdf

accesso aperto

Descrizione: Correspondence
Tipologia: Publisher's version/PDF
Dimensione 889.95 kB
Formato Adobe PDF
889.95 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/970539
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact